LB Pharmaceuticals (LBRX)

• Market cap: $1.38B
• 1 day: -0.37%
• 5 days: 17.82%
• 1 month: 39.98%
• 3 months: 50.09%
• 6 months: 100.25%
• Year to date: 134.83%
• 1 year: 177.46%
• 5 years: 177.46%
• 10 years: 177.46%
• Sector: Healthcare
• Industry: Biotechnology

About: LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Employees: 27